Prevalence Of Prostate Cancer Research Articles

Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study

Aim This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China. Methods A retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes. Results In total, 1086 patients with mHSPC and 679 patients with nmCRPC were included. From 2015 to 2020, the annual percentage of prevalent and incident cases of mHSPC decreased from 22.4% to 20.0% and 11.1% to 6.9%, respectively; for nmCRPC, these increased from 3.8% to 13.6% and 3.3% to 8.4%. Androgen-deprivation therapy and first-generation antiandrogens (bicalutamide or flutamide) were the most frequently prescribed prostate cancer–related medications at baseline and follow-up in patients with mHSPC. Bicalutamide was the most frequently prescribed prostate cancer–related medication during follow-up in patients with nmCRPC. For mHSPC, inpatient admission costs were the highest, with the median (interquartile range) costs per person-month being USD 403.00 (USD 85.50–1226.20), whereas outpatient visit costs were the highest for nmCRPC (USD 372.60 [USD 139.50–818.50]). Limitations EMR-based study design did not capture treatment patterns, HRU and associated costs, and healthcare encounters that occurred outside of participating hospitals, which could have led to underestimation of the true disease burden. Conclusions A contrasting trend of a decline in the prevalence and incidence of mHSPC and an increase in these for nmCRPC was observed between 2015 and 2020 in China. Androgen-deprivation therapy and first-generation antiandrogens were the most frequently prescribed prostate cancer–related medications. Healthcare resource utilization was driven by inpatient costs in mHSPC and outpatient costs in nmCRPC.

Assessment of Ki-67 expression in cases of prostatic carcinoma and its correlation with clinical outcomes.

Treatment decisions after diagnosis of clinically localized prostate cancer are difficult due to variability in tumor behavior. As there is a high prevalence of low-grade prostate cancer with an indolent course, we need improved markers of prostate cancer lethality in order to reduce the overtreatment. In the current study, we assessed Ki-67 expression in cases of prostate carcinoma and correlated its expression with clinical outcomes. It was a single-center retrospective descriptive type of study. A total of 50 cases were included. Diagnosed cases of adenocarcinoma on Transurethral Resection of the Prostate (TURP) chips and Trucut prostatic biopsies (Archival biopsy specimens) for whom five years follow-up was available from record files and/or telephonic interviews were included. The clinical outcomes (rate of distant metastases, disease specific survival, and overall survival) over a period of five years were recorded. In the current study, 78% of the cases of carcinoma prostate were positive for Ki-67 expression. The mean Ki-67 staining index was 15.22% among the cases. The cases with High Ki-67 Staining index had a significantly higher rate of distant metastasis, poor disease-specific survival, and overall survival compared to cases with low Ki-67 staining index. Ki-67 can be used along with the other established prognostic parameters to assess the lethality of prostate cancer.

Marijuana use may be associated with reduced prevalence of prostate cancer: A cross-sectional study using the national survey on drug use and health database.

101 Background: Preclinical data from cell lines and animal xenograft models support the anti-tumor effects of cannabinoids in prostate cancer (PC). Methods: We performed a cross-sectional study to investigate this association using National Survey on Drug Use and Health (NSDUH) data consisting of 2503 participants accrued from 2002 to 2020. Key independent variable was defined as current, former, and never users of marijuana (MJ). Dependent variable was self-reported PC (yes, no). Other MJ-related variables evaluated: age at first use, number of days used in the past 30 days, use of medical MJ, legality of MJ use in state of residence. Demographic variables assessed as potential confounders or covariates were: age, sex, race/ethnicity, education, marital status, total family income, insurance status, sexual identity, residence status, served in armed forces, cigarette smoking, and alcohol consumption. Multivariate (MV) logistic regression was employed to calculate odds ratios (OR) and 95th percentile confidence intervals (CI) to quantify relationship with MJ use in relation to PC status. Results: Prevalence of PC was significantly lower among current MJ users (46/145, 31.7%), and former users (323/1021, 31.6%) in comparison to non-users (534/1337, 39.9%, p < 0.001). Older MJ users (≥ 65) had significantly lower prevalence of PC compared to nonusers (36.4% vs. 42.4%, p = 0.016). A similar significant reduction was documented among non-Hispanic white (NHW) MJ users when compared to nonusers (28.9% vs. 38.3%, p < 0.001). There were no significant differences in the prevalence of PC between MJ users and non-users among the young (50-64) or other race/ethnicity. In MV logistic regression analyses, former MJ use was associated with a lower prevalence of PC compared to never use (OR = 0.74, 95% CI 0.62 - 0.90, p=0.001). Current MJ use also was suggestive of reduced prevalence but did not reach statistical significance (OR=0.77, 95% CI 0.52 – 1.14, p=0.198) possibly due to low sample size. Conclusions: Our findings provide additional data to link MJ use with low prevalence of PC, particularly in NHW. Future prospective studies using regulatory approved medical MJ are warranted. [Table: see text]

Discordant Molecular Imaging Findings with 2-[18F]FDG and [68Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer.

The prevalence of double primary prostate and bladder cancer is not uncommon. Though both share a common pathway of malignant transformation, they bear to differ in the case of 2-[18F]FDG PET/CT and [68Ga]Ga-PSMA uptake. We present a case of double primary cancer involving the bladder and prostate, where the prostatic primary showed intense [68Ga]Ga-PSMA uptake with non-avid skeletal and pulmonary metastases, which showed intense 2-[18F]FDG uptake, thus showing discordance due to different clonal origins.

Blood Pb levels are associated with prostate cancer prevalence among general adult males: Linking National Cancer Registry (2002–2017) and KNHANES (2008–2017) databases of Korea

BackgroundExposure to heavy metals may increase the risk of developing prostate cancer. However, these observations are often inconsistent and not based on clinically diagnosed cases. ObjectiveTo investigate the association of lead (Pb), cadmium (Cd), and mercury (Hg) exposure with clinically determined prostate cancer cases among adult males in South Korea. MethodsMetal biomonitoring data and cancer information from the general Korean population were extracted by linking National Cancer Center (NCC) cancer registration data (2002–2017) with Korea National Health and Nutrition Examination Survey (KNHANES) data (2008–2017). Among them, 46 prostate cancer cases (designated as ‘all-prostate’), including 25 diagnosed after heavy metal measurement (designated as ‘post-prostate’), and 93 matching controls were chosen. Logistic regression analysis was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) between the heavy metal levels and prostate cancer. ResultsPost-prostate patients exhibited higher blood Pb levels than controls (median 3.1 μg/dL vs. 2.38 μg/dL, p = 0.01). For all-prostate cancer, the OR of prostate cancer increased by 2.04-fold for every doubling of Pb levels (95% CI = 1.08–3.87, p = 0.03). The OR was also significantly elevated when comparing the third quartile (Q3) to the lowest quartile (Q1), with ORs ranging from 3.38 to 7.95, depending on model (p < 0.05). Blood Pb levels maintained a positive association with inconsistent significance for post-prostate cancer patients. For Cd and Hg, no statistically significant association was established. SignificanceBy linking two national health databases for the first time, we constructed an unbiased database of prostate cancer cases and matching controls. We found that blood Pb concentrations were associated with the risk of prostate cancer in Korean men at the current level of exposure.

Association between the metabolic score for insulin resistance and prostate cancer: a cross-sectional study in Xinjiang.

Insulin resistance is associated with the development and progression of various cancers. However, the epidemiological evidence for the association between insulin resistance and prostate cancer is still limited. To investigate the associations between insulin resistance and prostate cancer prevalence. A total of 451 patients who were pathologically diagnosed with prostate cancer in the First Affiliated Hospital of Xinjiang Medical University were selected as the case population; 1,863 participants who conducted physical examinations during the same period were selected as the control population. The metabolic score for insulin resistance (METS-IR) was calculated as a substitute indicator for evaluating insulin resistance. The Chi-square test and Mann-Whitney U test were performed to compare the basic information of the case population and control population. Univariate and multivariate logistic regression analyses to define factors that may influence prostate cancer prevalence. The generalized additive model (GAM) was applied to fit the relationship between METS-IR and prostate cancer. Interaction tests based on generalized additive model (GAM) and contour plots were also carried out to analyze the interaction effect of each factor with METS-IR on prostate cancer. METS-IR as both a continuous and categorical variable suggested that METS-IR was negatively associated with prostate cancer prevalence. Smoothed curves fitted by generalized additive model (GAM) displayed a nonlinear correlation between METS-IR and prostate cancer prevalence (P < 0.001), and presented that METS-IR was negatively associated with the odds ratio (OR) of prostate cancer. The interaction based on the generalized additive model (GAM) revealed that METS-IR interacted with low-density lipoprotein cholesterol (LDL-c) to influence the prostate cancer prevalence (P = 0.004). Contour plots showed that the highest prevalence probability of prostate cancer was achieved when METS-IR was minimal and low-density lipoprotein cholesterol (LDL-c) or total cholesterol (TC) was maximal. METS-IR is nonlinearly and negatively associated with the prevalence of prostate cancer. The interaction between METS-IR and low-density lipoprotein cholesterol (LDL-c) has an impact on the prevalence of prostate cancer. The study suggests that the causal relationship between insulin resistance and prostate cancer still needs more research to confirm.

Updated prevalence of latent prostate cancer in Chinese population and comparison of biopsy results: An autopsy-based study

Prostate cancer detected by autopsy is named latent prostate cancer. As the repertoire of clinical prostate cancer, latent cancer may better reflect the disease burden. Unlike clinical prostate specimens, which are obtained exclusively from biopsy-positive cases, prostate specimens obtained through autopsy provide information on biopsy-negative cases, helping calculate the true sensitivity of prostate biopsy. From 2014 to 2021, we collected autopsy specimens of the prostate from body donors in China and performed transperineal and transrectal biopsies on specimens before step-sectioning and pathological measurements. We found that the crude prevalence of latent prostate cancer in middle-aged and elderly men was 35.1% (81/231), which was higher than previous estimates for Chinese populations. The overall per-patient sensitivities of transperineal and transrectal biopsies were not significantly different (33.3% vs. 32.1%, p= 0.82), but the two approaches differed in preferential sampling area along the proximal-distal axis of the prostate. Transperineal biopsy had a higher sensitivity for detecting clinically significant lesions in the distal third (34.7% vs. 16.3%, p= 0.02) and distal half (30.6% vs. 18.1%, p= 0.04), while transrectal biopsy had a higher sensitivity for lesions in the proximal half (25.0% vs. 13.9%, p= 0.046). Both transperineal and transrectal methods of biopsy missed most small lesions (<0.1mL) and 35.3% (6/17) of large lesions (>0.5mL). In conclusion, the prevalence of latent prostate cancer in China has increased over the past 2 decades. Systematic transperineal and transrectal methods of biopsy had comparable sensitivities but had different preferential sampling areas. Both approaches miss one-third of large lesions.

The Up to Date Progress of Prostate Cancer Vaccines

The prostate cancer vaccine has significant influences on males, and the cancer among American men has second highest prevalence among all cancers. Both the prevalence and mortality rates of prostate cancer in America are increasing each year. Researchers have been working to improve and innovate the way prostate cancer is diagnosed and treated. One promising direction is immunotherapy. Scientists have been working on a vaccine for prostate cancer for decades, and FDA only passes Sipuleucel-T as prostate cancer vaccine, but many other prostate cancer vaccines have been developed. Therefore, after synthesizing many papers, this paper explains the principles, latest progress, the advantages and disadvantages of all the vaccines developed so far, and proposes that future researchers should improve the prostate cancer vaccine in the direction of combination therapy, and conduct in-depth research to explore the prostate cancer vaccines that are currently showing an excellent trend, and to optimize the Sipuleucel-T.

The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer

We introduce Promoter-Enhancer-Guided Interaction Networks (PENGUIN), a method for studying protein-protein interaction (PPI) networks within enhancer-promoter interactions. PENGUIN integrates H3K27ac-HiChIP data with tissue-specific PPIs to define enhancer-promoter PPI networks (EPINs). We validated PENGUIN using cancer (LNCaP) and benign (LHSAR) prostate cell lines. Our analysis detected EPIN clusters enriched with the architectural protein CTCF, a regulator of enhancer-promoter interactions. CTCF presence was coupled with the prevalence of prostate cancer (PrCa) single nucleotide polymorphisms (SNPs) within the same EPIN clusters, suggesting functional implications in PrCa. Within the EPINs displaying enrichments in both CTCF and PrCa SNPs, we also show enrichment in oncogenes. We substantiated our identified SNPs through CRISPR/Cas9 knockout and RNAi screens experiments. Here we show that PENGUIN provides insights into the intricate interplay between enhancer-promoter interactions and PPI networks, which are crucial for identifying key genes and potential intervention targets. A dedicated server is available at https://penguin.life.bsc.es/.

Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016

Background: Prostate cancer is the most common malignancy in men, which is the second leading cause of cancer-related death. The prevalence of prostate cancer in Iran is lower than in Western and European countries. Objectives: Our study presents an updated incidence rate of prostate cancer in Iran and its provinces, displays its trends, and adds its spatial distribution to the literature. Methods: We investigate the age-standardized incidence rates (ASIRs) per annum of prostate cancer from 2003 to 2016 in Iran, using the data of the cancer registration available by the Ministry of Health and Medical Education. Crude incidence rates were calculated by dividing incident cases by the population of the whole country and each province which was available on the website of Iran Statistic Center. Age standardization was done by the World Health Organization (WHO) standard population and presented according to age and province. Results: The crude number of incident prostate cancer cases in Iran was 49 188 between 2003 and 2016. Age-standardized incidence rate of prostate cancer showed an increasing trend from 4.46 in 2003 to 18.44 per 100 000 in 2016. Mazandaran (29.57 per 100 000 in 2008) and Esfahan (27.5 per 100 000 in 2016 and 26.51 per 100 000 in 2015) were provinces with the highest reported ASIRs, while Sistan and Baluchestan province had the lowest mean of ASIR (1.59 per 100 000) in the period of the study. Conclusions: The incidence of prostate cancer displays an increase of more than 4 times at the end of the study period. However, the increase in coverage of data recording and greater access to diagnostic tests during these years are effective in the reported ASIRS, but the steep slope in the incidence trend of prostate cancer compared to other cancers in Iran shows its capacity to become one of the health problems that underscore the necessity of implementation of control and prevention programs, especially in high-incidence provinces.

Abstract C007: Disparities in occurrence and outcome of male reproductive cancers in the United States Pacific Islander community

Abstract Data from the National Cancer Database indicates prostate cancer (CPa) prevalence in the Pacific Islander (PI) community to be nearly 1.6 times higher than the national standard. Recent data suggests that prostate cancer rates seen in United States PI men are comparable to that of African American men, the community with the longstanding recognition as having the highest rates of the disease in the US. PIs are defined as those originating from or being indigenous to the islands of Polynesia, Melanesia, and Micronesia including the US governed Hawaiian islands, Guam, Northern Marianas Islands, and American Samoa. PIs make up a grossly underrepresented minority group, often being overshadowed by their mainland Asian counterparts when aggregated together as a group defined as “AANHPI” in sociological and epidemiological data sets and studies. In addition, Pacific Islanders, at least in the mainland US, are considered a “new” minority population, and with the exception of those indigenous to US territories, the vast majority of the population are post 1970 first or second generation immigrants. Research into health disparities in the PI community is thus unsurprisingly sparse, and there is great work to be done to explore these alarming trends. The purposes of this study are threefold: further explore the data pertaining to prostate cancer prevalence in the pacific islander community; disaggregate the data between ethnic lines; and provide a foundation for future research that can further elucidate the causes and outcomes of this disease in the Pacific Islander community. Data was taken from the 2014 Native Hawaiian and Pacific Islander National Health Interview Survey (NHPI NHIS). The NHPI NHIS is a national survey administered by the CDC-NCHS to collect disease data including health condition and characteristics, health care access and service utilization but specific to the national NHPI population. Among 2588 participants, 4% indicated ever having been diagnosed with cancer among which prostate cancer was the second most commonly diagnosed. This study relies heavily on large-scale national questionnaires, thus future research should incorporate additional qualitative exploratory research, including targeted and ethnicity-specific canvassing and interviews in order to better understand the real life manifestations of the disease. The preliminary findings highlight an ever growing concern for the health outcomes of this community, and provide compelling evidence in support for both disaggregation of the community from Asian Americans, as well as interethnic disaggregation in data sets. A common thread of distancing between PI communities and the healthcare system was particularly evident, raising the concern that PIs are not being screened early enough and are not seeking life saving medical attention until advanced disease progression. A hopeful outcome of this study is a recognition that more outreach and community work must be done to bridge the gap between PIs and the Western healthcare system in order to mitigate the observed disparities. Citation Format: Nicholas A. Sowizral. Disparities in occurrence and outcome of male reproductive cancers in the United States Pacific Islander community [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C007.

Abstract A096: Exploring the influence of sociodemographic factors in a Puerto Rican population with a diagnosis of cancer

Abstract Introduction: Sociodemographic data plays a vital role in understanding the diverse factors that might influence health outcomes, especially in patients with a diagnosis of cancer. Understanding elements such as age, sex, race identification, insurance status, and family support can provide guidance to better improve quality of life. For example, family support can make a significant difference when facing the emotional and physical challenges of the disease. Meanwhile, a favorable health insurance can often lessen financial burdens associated with treatment. The objective of this study is to outline the sociodemographic profile of a Puerto Rican cohort with a diagnosis of cancer and create a landscape for other minority and cancer-affected populations. Methodology: A questionnaire that inquired about sociodemographic data and past medical history was distributed at COVID-19 vaccination clinics in Puerto Rico from December 2020 to June 2021. Participants who had a confirmed history or current diagnosis of cancer were included. Bivariate analyses were conducted. This research received IRB approval. Results: The study cohort included 115 participants with a current or past diagnosis of cancer: 67 were female and 48 were male, with a mean age of 69.5±12.4 and an age range of 23-95. The most prevalent identified types of cancer diagnoses were prostate (15.7%), breast (13.9%), colon (3.5%), and skin (3.5%). When assessing race, 64.3% identified as White, 27.0% as Other Race, 7.8.% as Black or African American, and 0.9% as American Indian or Alaska Native. The majority of participants identified as Hispanic or Latino (97.4%). When considering health insurance status, out of 95 participants who answered the inquiry, 81.1% had private insurance, 12.6% had public insurance, and 6.3% were not insured. There was no statistical difference in prevalence of sex (p=0.729) or race identification (p=0.060) within private insurance status. In terms of family nucleus and household support, 26.1% mentioned living on their own, 41.7% lived with one other person, 16.5% lived with 2 additional people, and 15.7% lived with 3 or more people in their nucleus. There was a significantly higher prevalence of females living on their own than males (p=0.005). Meanwhile, males were significantly more likely to live with one other person than females (p=0.022). There was no statistical difference between sex prevalence and living with two people (p=0.118) or three or more people (p=0.191) in the family nucleus. Conclusions: This study provides a valuable snapshot of current sociodemographic data of a Puerto Rican population with a diagnosis of cancer. There was a particular prevalence of prostate and breast cancer in the cohort and most participants were privately insured. Within the context of important family support, most lived with another person as part of the nucleus; however, males were more likely to live with an additional person. Studies emphasizing the importance of sociodemographic factors in this population are vital for improving healthcare outcomes. Citation Format: Humberto R. Nieves-Jiménez, Andrea Firpo-Pabón, Jean Carlos G. Martínez-Izquierdo, Manuel A. Colón-Terrón, Javier A. Vélez-Martínez, Rafael E. Morales-Grimany, Laura I. Ortiz-López, Sergio J. Báez-Juarbe, Diego B. Buitrago-Villamizar, Juan D. Mercado-Potes, Sebastián Portela-Colón, Fernando A. Sánchez-Pérez, Eric M. González-Morales. Exploring the influence of sociodemographic factors in a Puerto Rican population with a diagnosis of cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A096.

Association of triglyceride-glucose index with the risk of prostate cancer: a retrospective study.

Prostate cancer is the most common malignancy in men, and its incidence is increasing year by year. Some studies have shown that risk factors for prostate cancer are related to insulin resistance. The triglyceride-glucose (TyG) index is a marker of insulin resistance. We investigated the validity of TyG index for predicting prostate cancer and the dose-response relationship in prostate cancer in relation to it. To investigate the risk factors of TyG index and prostate cancer prevalence. This study was screened from the First Affiliated Hospital of Xinjiang Medical University and included 767 people, including 136 prostate cancer patients in the case group and 631 healthy people in the control group. The relationship between TyG index and the risk of prostate cancer was analyzed by one-way logistic regression, adjusted for relevant factors, and multi-factor logistic regression analysis was performed to further investigate the risk factors affecting the prevalence of prostate cancer. ROC curves and Restricted Cubic Spline were established to determine the predictive value and dose-response relationship of TyG index in prostate cancer. Blood potassium (OR = 0.056, 95% CI [0.021-0.148]), total cholesterol (OR = 1.07, 95% CI [0.792-1.444]) and education level (OR = 0.842, 95% CI [0.418-1.697]) were protective factors for prostate cancer, alkaline phosphatase, age, LDL, increased the risk of prostate cancer (OR = 1.016, 95% CI [1.006-1.026]) (OR = 139.253, 95% CI [18.523-1,046.893] (OR = 0.318, 95% CI [0.169-0.596]); TyG index also was a risk factor for prostate cancer, the risk increased with TyG levels,and persons in the TyGQ3 group (8.373-8.854 mg/dL) was 6.918 times (95% CI [2.275-21.043]) higher than in the Q1 group,in the TyGQ4 group (≥8.854) was 28.867 times of those in the Q1 group (95% CI [9.499-87.727]). TyG index may be a more accurate and efficient predictor of prostate cancer.

Prevalence and predictors of survival among patients with prostate cancer attending Nyeri County and referral hospital, Kenya: a review of records 2017-2022

Background: Prostate cancer is a significant health concern globally. The incidence rate of prostate cancer (PCa) has continued to rise in Kenya. This study aimed to investigate the prevalence of prostate cancer in patients attending Nyeri County and referral hospital in Kenya, identify predictors of survival, and assess the impact of treatment modalities on survival outcomes. Methods: A retrospective observational design was employed, analyzing data from 252 patient records documented between 2017 and 2022. Demographic characteristics, clinical features, treatment modalities, and survival outcomes were extracted and analyzed. Results: The prevalence of prostate cancer among the study population was found to be 10.84%. The majority of patients diagnosed with prostate cancer were aged 70 years or older, with none below 40 years. Most patients were residents of Nyeri County, and some came from neighboring counties in central Kenya. The overall survival rate for prostate cancer patients was 64.29%, indicating that 35.71% of patients died during the study period. Advanced age, comorbidities, and late-stage diagnosis were associated with lower survival rates. Multivariate analysis revealed that prostate cancer cases with hypertension were 2.91 times more likely to die compared to those without comorbidities (p=0.01, CI: 1.285051-6.597691). Conclusions: The study highlights a significant prevalence of prostate cancer in the region and emphasizes the need for enhanced management strategies. Early detection programs, tailored treatment approaches considering comorbidities, and improved access to healthcare services are recommended to enhance survival rates and overall management of prostate cancer in this population.

MORBIDITY OF PROSTATE CANCER AND FEATURES OF MEDICAL CARE FOR MEN IN THE SUBARCTIC REGION OF NORTH-WEST RUSSIA

Relevance: The need for epidemiological studies of prostate cancer is due to the fact that this type of oncology occupies one of the leading positions among other malignant tumors. Over the past ten years, there has been an increase in the incidence of prostate cancer by almost half. The aim of the study is to identify the features of the prevalence of prostate cancer and its consequences among residents of the Arkhangelsk region, as well as problems in the system of prevention, early diagnosis, medical care and rehabilitation of patients. Materials and methods: The information materials of the Unified State Interdepartmental Information and Statistical System of the Federal State Statistics Service were used. A retrospective analysis of the incidence and mortality of prostate cancer from 2012 to 2021 in the Arkhangelsk region was carried out. To assess the general and annual trend, its degree of reliability, a trend line was constructed and the value of the approximation coefficient R2 was calculated, which in all cases turned out to be acceptable. The results of the study: During the studied period of time, an increase in the incidence of prostate cancer was noted among men of the Arkhangelsk region and the Russian Federation. At the same time, the last decade has been marked by an increase in mortality from prostate cancer. In the diagnosis of prostate cancer in the early stages, the effective organization of the health care system is of great importance. Among them, special attention is paid to regional projects "Fight against oncological diseases". Conclusion. At the regional level, the organization of centers for the supply of specialized (oncological) medical care on the basis of medical organizations has made a great contribution to the early diagnosis of malignant neoplasms of the prostate gland. Such successes had a positive impact on the mortality and survival rates of cancer patients.

Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer.

Early identification of germline mutation carriers may be relevant for the optimal management of prostate cancer and to inform cancer risk in relatives. However, population minorities have limited access to genetic testing. The aim of this study was to describe the frequency of DNA repair gene pathogenic variants (PVs) among Mexican men with prostate cancer referred for Genomic Cancer Risk Assessment and testing. Patients diagnosed with prostate cancer who meet criteria for genetic testing and enrolled in the Clinical Cancer Genomics Community Research Network at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City were included. Descriptive statistics were performed using frequency and proportions for categorical variables and median and range for quantitative variables. X2 and t test were used for group comparisons. A total of 199 men were enrolled, median age at diagnosis was 66 (range 44-88) years; 45% were de novo metastatic and 44% were high- very high and 10% were intermediate risk group. Four (2%) had a pathogenic germline variant; one each of the following genes: ATM, CHEK2, BRIP1, and MUTYH (all monoallelic). Younger men at diagnosis were more likely to carry a PV than older age at diagnosis (56.7 vs. 66.4 years, P=.01). Our results showed a low prevalence of known prostate cancer associated PVs and no BRCA PVs in Mexican men with prostate cancer. This suggests that the genetic and/or epidemiologic risk factors for prostate cancer are not well characterized in this specific population.

The Prevalence and Management of Synchronous Prostate and Rectal Cancer

Synchronous prostate and rectal cancer is rare and guidelines for co-management are not well established. This case series explores the prevalence of synchronous diagnosis and different treatment paradigms to propose a standardized approach to management. We retrospectively reviewed all radiation treatments between 1/2017 and 12/2022 for curative intent treatment to both prostate and rectal cancer. Synchronous was defined as rectal or prostate cancer diagnosed within a 6-month period of each other. We collected baseline characteristics and treatment paradigms including the sequencing of chemoradiation (CRT), chemotherapy (CT), prostate boost, and surgery. There were 10 out of 2204 total treated patients with prostate or rectal primary noted to have a synchronous diagnosis (0.45%). Table 1 shows characteristics and treatment approach for all patients with 50% receiving CRT and 50% CT alone first. At a median FU of 21.4 months, 2 patients did not complete therapy due to patient choice and both had progression of disease (POD). After completion of CRT, 6 patients underwent rectal surgery with 2 pathological complete response, and 2 patients proceeded with a Watch and Wait approach with clinical complete response on MRI. Prostate boost was delivered equally as often pre-surgery as post-surgery with both SBRT, EBRT and Seed Implant used. There was no grade 3+ RT related toxicity in the patients who completed all therapy. This series represents one of the largest synchronous prostate and rectal cancer cohorts treated with curative intent. Future collaborative work is needed to develop guidelines in the treatment of synchronous prostate and rectal cancers. Although a rare diagnosis, the heterogeneity of approaches has led us to propose a standardized approach to management of synchronous diagnosis with upfront chemotherapy followed by EBRT inclusive of prostate and rectum followed by boost via brachytherapy (SBRT in non-candidates).

Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data.

The current prostate cancer (PCa) screening standard of care (SOC) leads to unnecessary biopsies and overtreatment because decisions are guided by prostate-specific antigen (PSA) levels, which have low specificity in the gray zone (3-10 ng/mL). New risk assessment tools (RATs) aim to improve biopsy decision-making. We constructed a modeling framework to assess new RATs in men with gray zone PSA from the British Columbia healthcare system's perspective. We evaluated the cost-effectiveness of a new RAT used in biopsy-naïve men aged 50+ with a PSA of 3-10 ng/mL using a time-dependent state-transition model. The model was informed by engaging patient partners and using linked administrative health data, supplemented with published literature. The incremental cost-effectiveness ratio and the probability of the RAT being cost-effective were calculated. Probabilistic analysis was used to assess parameter uncertainty. In the base case, a RAT based on an existing biomarker's characteristics was a dominant strategy associated with a cost savings of $44 and a quality-adjusted life years (QALY) gain of 0.00253 over 18 years of follow-up. At a cost-effectiveness threshold of $50,000/QALY, the probability that using a RAT is cost-effective relative to the SOC was 73%. Outcomes were sensitive to RAT costs and accuracy, especially the detection rate of high-grade PCa. Results were also impacted by PCa prevalence and assumptions about undetected PCa survival. Our findings showed that a more accurate RAT to guide biopsy can be cost-effective. Our proposed general model can be used to analyze the cost-effectiveness of any novel RAT.

The prevalence of prostate cancer in Pakistan: A systematic review and meta-analysis

BackgroundProstate cancer is a significant public health issue, ranking as the second most common cancer and the fifth leading cause of cancer-related deaths in men. In Pakistan, the prevalence of prostate cancer varies significantly across published articles. This study aimed to determine the pooled prevalence of prostate cancer and its associated risk factors in Pakistan. MethodsMEDLINE (via PubMed), Web of Science, Google Scholar, and local databases were searched from inception until March 2023, using key search terms related to the prevalence of prostate cancer. We considered a random-effects meta-analysis to derive the pooled prevalence and relative risks with 95% CIs. Two investigators independently screened articles and performed data extraction and risk of bias analysis. We also conducted meta-regression analysis and stratification to investigate heterogeneity. This study protocol was registered at PROSPERO, number CRD42022376061. ResultsOur meta-analysis incorporated 11 articles with a total sample size of 184,384. The overall pooled prevalence of prostate cancer was 5.20% (95% CI: 3.72–6.90%), with substantial heterogeneity among estimates (I2 = 98.5%). The 95% prediction interval of prostate cancer was ranged from 1.74%–10.35%. Subgroup meta-analysis revealed that the highest pooled prevalence of prostate cancer was in Khyber Pakhtunkhwa (8.29%; 95% CI: 6.13–10.74%, n = 1), followed by Punjab (8.09%; 95% CI:7.36–8.86%, n = 3), while the lowest was found in Sindh (3.30%; 95% CI: 2.37–4.38%, n = 5). From 2000 to 2010 to 2011–2023, the prevalence of prostate cancer increased significantly from 3.88% (95% CI: 2.72–5.23%) to 5.80% (95% CI: 3.76–8.24%). ConclusionsOur meta-analysis provides essential insights into the prevalence of prostate cancer in Pakistan, highlighting the need for continued research and interventions to address this pressing health issue.

Network analysis and molecular docking studies of quercetin as a potential treatment for prostate cancer.

Globally, the prevalence of prostate cancer is only the second to lung cancer. In Africa however, the commonest cancer among men is cancer of the prostate. The use of natural compounds from plants such as quercetin is being explored as a potential cure. Quercetin is a plant-based flavonoid that has anti-inflammatory, antioxidant and anticancer properties. Although quercetin has been extensively studied, its chemo preventive mode of action is not well-understood. The molecular targets and potential mechanisms underlying the action of quercetin against prostate cancer were identified and validated using network pharmacology and molecular docking methods. The biological targets of quercetin and targets associated with prostate cancer were obtained through database mining. Overlapping targets associated with quercetin and prostate cancer were identified and used to construct a compound-disease target (C-D) network and the targets were subjected to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction analysis (PPI). A disease target- pathway network was constructed and then merged with C-D network to form a compound-disease_target-pathway (C-D-P) network. Hub targets were obtained from the C-D-P and PPI networks. The binding affinities between quercetin and the retrieved hub targets were identified. Pathway enrichment analysis showed that prostate cancer associated quercetin targets were mainly linked with pathways such as the cancer signaling pathways (HIF-1 and ErbB) and hepatitis B. Basing on the PPI and C-D-P network analysis STAT3, TP53, MAPK1, MAPK3 and KRAS were identified as the main targets and were subjected to molecular docking. The results showed quercetin's ability to stably bind to the key targets. In conclusion, this study showed the potential molecular targets and mode of action of quercetin in prostate cancer treatment. This can potentially inform the future use of quercetin in the treatment of prostate cancer.